SDGR

Analyst Note: Schrödinger, Inc. (SDGR)

Date: 2026-06-20 Current Price: $15.76

1. Structural Readiness

• Conservative Entry: Not yet triggered (awaiting confirmed breakout close).
• Aggressive/Pre-Breakout Entry: $15.76 (Current Price). This represents a "partial" position entry based on the structural integrity of the support, not a confirmed breakout signal.
• Breakout Level: Not yet defined in the current snapshot; requires a close above the resistance of the forming coil.
• Current Price: $15.76.
• Extension: Not applicable (price is within the consolidation range, not extended above the breakout).
• ATR Context: Current ATR is 5.4% (High). This indicates elevated volatility, which is consistent with a forming structure in a high-beta growth sector. It suggests wider stop-losses are required if sizing a pre-breakout position, but also signals potential for a sharp move once the breakout fires.

2. Thesis Layer

• Primary Secular Theme: Biotech & GLP-1 → Platforms, Tools & CRO/CDMO.
• Role & Directness: Schrödinger is a Tier Direct beneficiary. The company operates as a foundational platform provider, not merely a service vendor. Its physics-based computational platform is positioned as a critical infrastructure layer for the "predict-first" paradigm in drug discovery.
• Thesis Weighting: The company is a pure-play on the digitization of R&D. As the industry shifts toward AI-driven and computational-first approaches to reduce the time and cost of molecular discovery, Schrödinger's role as the enabler of this shift provides high conviction. The "Biotech & GLP-1" theme is the primary driver, but the exposure is structural (platform) rather than cyclical (single asset), offering a more durable secular tailwind than pure-play biotech firms.

3. Business Analysis

Schrödinger operates a dual-engine business model: a Software Platform and a Drug Discovery Services arm (including its own clinical pipeline).

• Software Platform (The Core Engine):
• Model: The company licenses its physics-based computational platform to biopharmaceutical and industrial companies, academic institutions, and government labs. Revenue streams include software product licenses, hosted subscriptions, maintenance, professional services, and "contributions" (revenue sharing on successful drug candidates).
• Evidence of Traction:
• Customer Concentration: As of Dec 31, 2025, the top 20 pharmaceutical companies (by 2024 revenue) accounted for $73.7 million (37%) of software revenue and $80.8 million (41%) of Annual Contract Value (ACV). This indicates deep penetration into the most valuable R&D organizations.
• ACV Growth: Management expects full-year 2026 ACV to be $218 million to $228 million, representing 10% to 15% growth.
• Hosted Revenue Shift: Hosted revenue (SaaS-like) contributed $12.1 million (34%) of software total in Q2 2026, up from 24% in Q1 2025, signaling a successful transition to recurring revenue models.
• Customer Quality: The average ACV per commercial customer with >$1.0M ACV grew to $3.9 million in 2025, up from $3.3 million in 2024, demonstrating successful upselling and deeper integration.

• Drug Discovery Services & Pipeline:
• Model: The company leverages its platform to identify novel molecules, which it then advances into clinical trials. It also collaborates with partners on specific programs.
• Evidence of Progress:
• Clinical Milestones: As of Feb 2026, the company initiated dosing in a Phase 1 trial for SGR-1505 (relapsed/refractory B-cell malignancies).
• Collaborations: There are 20 active collaborative drug discovery programs covering oncology, antifungal, fibrosis, and metabolic diseases.
• Strategic Pivot: Management expects clinical activities to be "largely complete by the end of 2026," with R&D spending for the full year 2026 estimated at $10 million to $15 million. This suggests a strategic wind-down of internal clinical execution to seek partners for mid- and late-stage development, reducing capital intensity.

• Revenue Recognition:
• The company expects to recognize approximately 55% of its March 31, 2026 remaining performance obligations in the next 12 months, providing a clear visibility window for near-term revenue.

4. Archetype and Conviction

• Archetype: Growth Leader.
• Fit: The company exhibits the characteristics of a high-quality compounder transitioning into a mature growth phase. It has achieved significant scale (top 20 pharma penetration) and is optimizing its business model (shifting to hosted revenue, reducing internal clinical spend).
• Margin Inflector: The shift from pure licensing to hosted subscriptions (34% of software total) and the reduction of R&D spend (to $10-15M) as clinical activities wind down should improve operating leverage.
• Valuation Context: While specific P/E or P/S multiples are not provided in the evidence, the "Growth Leader" archetype combined with a 10-15% ACV growth rate and a pivot to lower-cost clinical models suggests the market is pricing in a transition from high-growth/high-burn to efficient growth.
• Conviction Stack:
• Thesis Strength: High. The "predict-first" paradigm is a structural shift in pharma R&D, and Schrödinger is a primary enabler.
• Evidence Quality: Strong. The evidence (E1-E18) provides concrete, quantitative backing for customer retention, ACV growth, and the strategic pivot.
• Structural Quality: The "forming" coil indicates the market is digesting the recent guidance and the strategic pivot. The high ATR (5.4%) suggests volatility is present but contained within the structure.
• Rerating Potential: Significant. If the company successfully executes the wind-down of clinical activities and continues to expand its hosted software footprint, the multiple could expand as the business model becomes more predictable and capital-efficient.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• A significant miss on the $218M-$228M ACV guidance for 2026.
• Failure to secure partners for the mid- and late-stage clinical assets, leading to a prolonged burn of the $10-15M R&D budget without external validation.
• What Would Strengthen:
• A confirmed breakout above the forming coil resistance.
• Announcement of a major partnership or licensing deal for a late-stage asset (SGR-1505 or others).
• Further acceleration in hosted revenue percentage (e.g., exceeding 40% of software total).
• Gaps in Evidence:
• Profitability Timeline: The evidence provides guidance on ACV and R&D spend but does not explicitly state the path to GAAP profitability or the current cash burn rate relative to the cash balance.
• Specific Product Metrics: While "Bunsen" (agentic AI co-scientist) is mentioned as an upcoming release, there is no data on its adoption rate or impact on ACV in the current period.
• Competitive Landscape: No direct comparison of Schrödinger's market share or pricing power against emerging AI-native competitors is provided in the evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Top 20 pharma companies account for 41% of ACV; ACV growth guidance of 10-15% for 2026; strategic pivot to wind down clinical activities to reduce R&D spend to $10-15M. Key risks: Failure to partner on clinical assets leading to extended cash burn; volatility in biotech sector causing customer capex cuts; execution risk on new AI product "Bunsen". Sizing hint: Position size should reflect the "forming" status; allocate a partial position now with the remainder reserved for a confirmed breakout close. Expected path: Management expects clinical activities to conclude by end of 2026, shifting the company toward a higher-margin software and partnership model, which should stabilize the stock price and allow for a breakout. Expected horizon: 6 to 12 months for the clinical wind-down to complete and the new business model to be fully priced in.